Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 May;84(9):1179–1184. doi: 10.1054/bjoc.2001.1784

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study

J Y Douillard 1, D Lerouge 2, A Monnier 3, J Bennouna 1, A M Haller 4, X S Sun 3, D Assouline 5, B Grau 6, A Rivière 2
PMCID: PMC2363882  PMID: 11336467

Abstract

The efficacy and toxicity of combined paclitaxel and gemcitabine was evaluated in 54 chemotherapy-naive patients with metastatic non-small cell lung cancer (NSCLC). Gemcitabine i.v. 1000 mg/m2was administered on days 1 and 8 and paclitaxel 200 mg/m2as a continuous 3-hour infusion on day 1. Treatment was repeated every 21 days. Patients had a median age of 53 years. ECOG performance status was 0 or 1 in 48 patients. 41 patients (75.9%) had initial stage IV disease; histology was mainly adenocarcinoma (46.3%). 2 patients (4.3%) achieved a complete response and 15 (31.9%) achieved a partial response giving an overall response rate of 36.2% (95% CI: 22.4–49.9%); 19 patients (40.4%) had stable disease and 10 (21.3%) had progressive disease. The median survival time was 51 weeks (95% CI: 46.5–59.3), with a 1-year survival probability of 0.48 (95% CI: 0.34–0.63). Grade 3/4 neutropenia and febrile neutropenia occurred in 15.2% and 2.2% of courses, respectively. Grade 3/4 thrombocytopenia was rare (1.8% of courses). Peripheral neurotoxicity developed in 25 patients (47.2%), mostly grade 1/2. Arthalgia/myalgia was observed in 30 patients (56.6%), generally grade 1 or 2. Grade 3 abnormal levels of serum glutamate pyruvate transaminase (SGPT) and serum glutamate oxaloacetate transaminase (SGOT) occurred in 5 patients (9.4%) and 1 patient (1.9%), respectively. Combined paclitaxel and gemcitabine is an active and well-tolerated regimen for the treatment of advanced NSCLC, and warrants further investigation in comparative, randomized trials. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: paclitaxel, gemcitabine, chemotherapy, non-small cell lung cancer

Full Text

The Full Text of this article is available as a PDF (70.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abratt R. P., Bezwoda W. R., Goedhals L., Hacking D. J. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 1997 Feb;15(2):744–749. doi: 10.1200/JCO.1997.15.2.744. [DOI] [PubMed] [Google Scholar]
  2. Anderson H., Lund B., Bach F., Thatcher N., Walling J., Hansen H. H. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994 Sep;12(9):1821–1826. doi: 10.1200/JCO.1994.12.9.1821. [DOI] [PubMed] [Google Scholar]
  3. Chang A. Y., Kim K., Glick J., Anderson T., Karp D., Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst. 1993 Mar 3;85(5):388–394. doi: 10.1093/jnci/85.5.388. [DOI] [PubMed] [Google Scholar]
  4. Crinò L., Scagliotti G., Marangolo M., Figoli F., Clerici M., De Marinis F., Salvati F., Cruciani G., Dogliotti L., Pucci F. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1997 Jan;15(1):297–303. doi: 10.1200/JCO.1997.15.1.297. [DOI] [PubMed] [Google Scholar]
  5. Depierre A., Chastang C., Quoix E., Lebeau B., Blanchon F., Paillot N., Lemarie E., Milleron B., Moro D., Clavier J. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol. 1994 Jan;5(1):37–42. doi: 10.1093/oxfordjournals.annonc.a058687. [DOI] [PubMed] [Google Scholar]
  6. Frasci G., Panza N., Comella P., Nicolella G. P., Natale M., Manzione L., Bilancia D., Cioffi R., Maiorino L., De Cataldis G. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group. J Clin Oncol. 1999 Aug;17(8):2316–2325. doi: 10.1200/JCO.1999.17.8.2316. [DOI] [PubMed] [Google Scholar]
  7. Fukuoka M., Takada M., Yokoyama A., Kurita Y., Niitani H. Phase II studies of gemcitabine for non-small cell lung cancer in Japan. Semin Oncol. 1997 Apr;24(2 Suppl 7):S7–42-S7-46. [PubMed] [Google Scholar]
  8. Gatzemeier U., Shepherd F. A., Le Chevalier T., Weynants P., Cottier B., Groen H. J., Rosso R., Mattson K., Cortes-Funes H., Tonato M. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer. 1996 Feb;32A(2):243–248. doi: 10.1016/0959-8049(95)00444-0. [DOI] [PubMed] [Google Scholar]
  9. Georgoulias V., Kouroussis C., Androulakis N., Kakolyris S., Dimopoulos M. A., Papadakis E., Bouros D., Apostolopoulou F., Papadimitriou C., Agelidou A. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol. 1999 Mar;17(3):914–920. doi: 10.1200/JCO.1999.17.3.914. [DOI] [PubMed] [Google Scholar]
  10. Giaccone G., Splinter T. A., Debruyne C., Kho G. S., Lianes P., van Zandwijk N., Pennucci M. C., Scagliotti G., van Meerbeeck J., van Hoesel Q. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1998 Jun;16(6):2133–2141. doi: 10.1200/JCO.1998.16.6.2133. [DOI] [PubMed] [Google Scholar]
  11. Hainsworth J. D., Burris H. A., 3rd, Erland J. B., Morrissey L. H., Meluch A. A., Kalman L. A., Hon J. K., Scullin D. C., Jr, Smith S. W., Greco F. A. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer. 1999 Mar 15;85(6):1269–1276. doi: 10.1002/(sici)1097-0142(19990315)85:6<1269::aid-cncr8>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  12. Hainsworth J. D., Urba W. J., Hon J. K., Thompson K. A., Stagg M. P., Hopkins L. G., Thomas M., Greco F. A. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial. Eur J Cancer. 1998 Apr;34(5):654–658. doi: 10.1016/s0959-8049(97)10103-4. [DOI] [PubMed] [Google Scholar]
  13. Johnson D. H., Paul D. M., Hande K. R., Shyr Y., Blanke C., Murphy B., Lewis M., De Vore R. F., 3rd Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol. 1996 Jul;14(7):2054–2060. doi: 10.1200/JCO.1996.14.7.2054. [DOI] [PubMed] [Google Scholar]
  14. Kroep J. R., Giaccone G., Voorn D. A., Smit E. F., Beijnen J. H., Rosing H., van Moorsel C. J., van Groeningen C. J., Postmus P. E., Pinedo H. M. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol. 1999 Jul;17(7):2190–2197. doi: 10.1200/JCO.1999.17.7.2190. [DOI] [PubMed] [Google Scholar]
  15. Langer C. J., Leighton J. C., Comis R. L., O'Dwyer P. J., McAleer C. A., Bonjo C. A., Engstrom P. F., Litwin S., Ozols R. F. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995 Aug;13(8):1860–1870. doi: 10.1200/JCO.1995.13.8.1860. [DOI] [PubMed] [Google Scholar]
  16. Lilenbaum R. C., Green M. R. Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol. 1993 Jul;11(7):1391–1402. doi: 10.1200/JCO.1993.11.7.1391. [DOI] [PubMed] [Google Scholar]
  17. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  18. Mountain C. F. Revisions in the International System for Staging Lung Cancer. Chest. 1997 Jun;111(6):1710–1717. doi: 10.1378/chest.111.6.1710. [DOI] [PubMed] [Google Scholar]
  19. Murphy W. K., Fossella F. V., Winn R. J., Shin D. M., Hynes H. E., Gross H. M., Davilla E., Leimert J., Dhingra H., Raber M. N. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993 Mar 3;85(5):384–388. doi: 10.1093/jnci/85.5.384. [DOI] [PubMed] [Google Scholar]
  20. Noble S., Goa K. L. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 1997 Sep;54(3):447–472. doi: 10.2165/00003495-199754030-00009. [DOI] [PubMed] [Google Scholar]
  21. Pirker R., Krajnik G., Zöchbauer S., Malayeri R., Kneussl M., Huber H. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 1995 Oct;6(8):833–835. doi: 10.1093/oxfordjournals.annonc.a059324. [DOI] [PubMed] [Google Scholar]
  22. Plunkett W., Huang P., Xu Y. Z., Heinemann V., Grunewald R., Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995 Aug;22(4 Suppl 11):3–10. [PubMed] [Google Scholar]
  23. Rowinsky E. K., Donehower R. C. Paclitaxel (taxol) N Engl J Med. 1995 Apr 13;332(15):1004–1014. doi: 10.1056/NEJM199504133321507. [DOI] [PubMed] [Google Scholar]
  24. Sandler A. B., Nemunaitis J., Denham C., von Pawel J., Cormier Y., Gatzemeier U., Mattson K., Manegold C., Palmer M. C., Gregor A. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000 Jan;18(1):122–130. doi: 10.1200/JCO.2000.18.1.122. [DOI] [PubMed] [Google Scholar]
  25. Schiff P. B., Fant J., Horwitz S. B. Promotion of microtubule assembly in vitro by taxol. Nature. 1979 Feb 22;277(5698):665–667. doi: 10.1038/277665a0. [DOI] [PubMed] [Google Scholar]
  26. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1–10. doi: 10.1016/0197-2456(89)90015-9. [DOI] [PubMed] [Google Scholar]
  27. Sørensen J. B., Stenbygaard L. E., Dombernowsky P., Hansen H. H. Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer. Ann Oncol. 1999 Sep;10(9):1043–1049. doi: 10.1023/a:1008352900990. [DOI] [PubMed] [Google Scholar]
  28. Wiseman L. R., Spencer C. M. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging. 1998 Apr;12(4):305–334. doi: 10.2165/00002512-199812040-00005. [DOI] [PubMed] [Google Scholar]
  29. Yokoyama A., Nakai Y., Yoneda S., Kurita Y., Niitani H. Activity of gemcitabine in the treatment of patients with non-small cell lung cancer: a multicenter phase II study. Anticancer Drugs. 1997 Jul;8(6):574–581. doi: 10.1097/00001813-199707000-00004. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES